# A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

> **NCT00710684** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 682 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SB-742457 15mg
- **DRUG:** SB-742457 35mg
- **DRUG:** Placebo
- **DRUG:** donepezil 5-10mg

## Key facts

- **NCT ID:** NCT00710684
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-01
- **Primary completion:** 2010-05-21
- **Final completion:** 2010-11-16
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710684, "A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00710684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*